Evaluating Treatment Efficacy in Intimal Sarcoma: A Case Cohort Analysis

Background Intimal sarcoma (IS) represents a rare and aggressive subtype of sarcoma predominantly impacting the heart and major blood vessels, posing significant challenges in both diagnosis and surgical intervention. Despite the administration of anthracycline-based regimens in advanced stages, the prognosis remains unfavorable. Methods This study aims to analyze the clinical characteristics of the disease and to evaluate the efficacy and safety of various treatment modalities. Results The findings underscores the limited therapeutic options, which generally encompass anthracyclines, taxanes, and anti-angiogenic therapies, suggesting the feasibility of anti-angiogenic therapy and CDK4/6 inhibitors, thereby contributing to an enhanced understanding and management of this uncommon malignancy. Conclusions IS has a high postoperative recurrence rate, and adjuvant therapy may be beneficial. Anti-angiogenic therapy shows efficacy with low cardiovascular risk, and CDK4/6 inhibitors are also effective.